Finance

Lists
Why is URGN down 3,82%?
Dive Deeper
URGN:NASDAQ
Urogen Pharma Ltd
US$36,80
-3,82%
(-1,46) 1D
14 ຕ.ລ., 15 ໂມງ 40 ນາທີ 33 ວິນາທີ GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for URGN...
Open
US$37,96
High
US$39,09
Low
US$36,72
Mkt. cap
1,80 ຕື້
Avg. vol.
887,34 ພັນ
Volume
730,75 ພັນ
52-wk high
US$50,81
52-wk low
US$16,36
EPS
US$-1,98
Beta
1,57
Shares outstanding
48,88 ລ້ານ
No. of employees
300
Open
US$37,96
High
US$39,09
Low
US$36,72
Mkt. cap
1,80 ຕື້
Avg. vol.
887,34 ພັນ
Volume
730,75 ພັນ
52-wk high
US$50,81
52-wk low
US$16,36
EPS
US$-1,98
Beta
1,57
Shares outstanding
48,88 ລ້ານ
No. of employees
300
News stories
From web sources and news partners
Seeking Alpha
Seeking Alpha
·
1 ມື້ກ່ອນ
UroGen Pharma: An Emerging GARP Stock
About Urogen Pharma Ltd
CEO-
Employees300
Founded2004
Headquartersນິວຢອກ, ລັດນີວຢອກ, ສະຫະລັດ
SectorBiotechnology
Websiteurogen.com
Analyst ratings
Based on 5 analysts giving stock ratings to URGN in the past 3 months
Strong buy
Buy
4
Hold
1
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for URGN in the last 3 months.
Highest
Current US$36,80
US$75,00 (+103,80%)
Average
US$60,20 (+63,59%)
Lowest
US$48,00 (+30,43%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
US$75,00
+103,8%
08/21/2026
Leland Gershell
Oppenheimer
Buy
Reiterated
US$60,00
+63%
08/06/2026
Paul Choi
Goldman Sachs
Hold
Maintained
US$48,00
+30,4%
08/05/2026
Michael Schmidt
Guggenheim
Buy
Maintained
US$58,00
+57,6%
08/05/2026
Tara Bancroft
TD Cowen
Buy
Reiterated
US$60,00
+63%
08/05/2026
Unknown Analyst
Guggenheim
Buy
Maintained
US$32,00
-13%
06/03/2026
Kevin DeGeeter
Ladenburg Thalmann & Co.
Buy
Initiated
US$43,00
+16,8%
05/11/2026
Kelsey Goodwin
Piper Sandler
Buy
Maintained
US$40,00
+8,7%
04/20/2026
Amin Makarem
Jefferies
Buy
Initiated
US$40,00
+8,7%
04/09/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
ກ.ຍ. 2025
ທ.ວ. 2025
ມ.ນ. 2026
ມິ.ຖ. 2026
Revenue
27,48 ລ້ານ
37,84 ລ້ານ
50,96 ລ້ານ
72,46 ລ້ານ
Cost of goods sold
3,28 ລ້ານ
3,29 ລ້ານ
4,14 ລ້ານ
6,57 ລ້ານ
Cost of revenue
3,28 ລ້ານ
3,29 ລ້ານ
4,14 ລ້ານ
6,57 ລ້ານ
Research and development expenses
14,01 ລ້ານ
14,31 ລ້ານ
15,60 ລ້ານ
17,34 ລ້ານ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
37,58 ລ້ານ
39,35 ລ້ານ
51,49 ລ້ານ
48,44 ລ້ານ
Operating expense
51,59 ລ້ານ
53,66 ລ້ານ
67,08 ລ້ານ
65,77 ລ້ານ
Total operating expenses
54,87 ລ້ານ
56,95 ລ້ານ
71,22 ລ້ານ
72,34 ລ້ານ
Operating income
-27,39 ລ້ານ
-19,12 ລ້ານ
-20,26 ລ້ານ
111,00 ພັນ
Other non operating income
-4,82 ລ້ານ
-4,66 ລ້ານ
-4,83 ລ້ານ
-4,89 ລ້ານ
EBT including unusual items
-34,40 ລ້ານ
-26,64 ລ້ານ
-28,35 ລ້ານ
-8,72 ລ້ານ
EBT excluding unusual items
-34,40 ລ້ານ
-26,64 ລ້ານ
-28,35 ລ້ານ
-8,72 ລ້ານ
Income tax expense
-1,05 ລ້ານ
-275,00 ພັນ
-4,77 ລ້ານ
5,63 ລ້ານ
Effective tax rate
3,06%
1,03%
16,83%
-64,54%
Other operating expenses
-
-
-
-
Net income
-33,35 ລ້ານ
-26,36 ລ້ານ
-23,57 ລ້ານ
-14,35 ລ້ານ
Net profit margin
-121,34%
-69,68%
-46,26%
-19,81%
Earnings per share
-0,69
-0,53
-0,47
-0,28
Interest and investment income
1,18 ລ້ານ
908,00 ພັນ
931,00 ພັນ
946,00 ພັນ
Interest expense
-3,37 ລ້ານ
-3,77 ລ້ານ
-4,18 ລ້ານ
-4,89 ລ້ານ
Net interest expenses
-2,20 ລ້ານ
-2,86 ລ້ານ
-3,25 ລ້ານ
-3,94 ລ້ານ
Depreciation and amortization charges
-
-
-
-
EBITDA
-27,31 ລ້ານ
-19,04 ລ້ານ
-20,19 ລ້ານ
189,00 ພັນ
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
ແອັບຂອງ Google